Calcium Channel Blocker Global Market Report 2024

The calcium channel blocker market size has grown strongly in recent years. It will grow from $14.72 billion in 2023 to $15.75 billion in 2024 at a compound annual growth rate (CAGR) of 7.0%. The growth observed in the historical period within the usage of calcium channel blockers can be attributed to various factors, including an increased incidence of cardiovascular diseases, a growing aging population, advancements in medical research leading to better treatment options, shifts in lifestyle patterns, and heightened awareness among individuals about cardiovascular health.

The calcium channel blocker market size is expected to see strong growth in the next few years. It will grow to $20.64 billion in 2028 at a compound annual growth rate (CAGR) of 7.0%. Anticipated growth in the upcoming period within the usage of calcium channel blockers can be linked to several key factors, notably the escalating global burden of cardiovascular diseases, the trend towards personalized medicine, improved access to healthcare services, expansions in the range of indications for these medications, and regulatory approvals driving market expansions. Major trends expected in the forecast period encompass overall market growth, technological advancements in treatment methods, shifts in the regulatory landscape affecting these medications, competitive analysis within the pharmaceutical industry, considerations of patient preferences, and heightened awareness among patients regarding treatment options.

The growth of the calcium channel blocker market is anticipated to be propelled by the increasing prevalence of cardiovascular diseases. Cardiovascular diseases, affecting the heart or blood vessels, have become more prevalent, leading to a heightened demand for interventions such as calcium channel blockers (CCBs). These medications are employed to reduce the risk of heart failure and stroke. An August 2022 report from the American College of Cardiology predicts a rise in cardiovascular risk factors in the United States between 2025 and 2060. Notably, diabetes is projected to increase by 39.3%, dyslipidemia by 27.6%, hypertension by 25.1%, and obesity by 18.3%. Substantial increases are also expected in cardiovascular disease rates, including stroke, heart failure, ischemic heart disease, and heart attack. This surge in cardiovascular conditions is driving the growth of the calcium channel blocker market.

The growth of the calcium channel blocker market is further supported by the increasing healthcare expenditure. Healthcare expenditure refers to the total resources allocated and spent on healthcare services and related activities within a specific timeframe. Elevated healthcare spending contributes to a favorable environment for the calcium channel blocker market, facilitating better access, affordability, research and development, and overall patient care. According to the 2021-2030 National Health Expenditure report by the Centers for Medicare & Medicaid Services, national health spending in the United States is expected to increase by an average of 5.1% annually between 2021 and 2030, reaching nearly $6.8 trillion. The report also forecasts a 7.2% annual increase in Medicare spending and a 5.6% annual rise in Medicaid spending during the same period, highlighting the significant role of healthcare expenditure in driving the growth of the calcium channel blocker market.

Product innovation emerges as a key trend in the calcium channel blocker market, with major companies emphasizing the development of innovative products to maintain their market position. For example, in June 2022, CMP Pharma, a US-based pharmaceutical manufacturing company, introduced Norliqva, the first and only oral liquid solution of the besylate salt of amlodipine - an extended-release calcium channel blocker. Norliqva addresses the challenges associated with crushing or synthesizing amlodipine tablets, ensuring uniform dosing and bioequivalence. This innovative product caters to patients who require amlodipine but face difficulties with swallowing or are unable to swallow. The focus on product innovation is a testament to the dynamic nature of the calcium channel blocker market and the commitment of major companies to meeting evolving healthcare needs.

Major companies within the calcium channel blocker market are strategically developing innovative products, specifically tablets tailored for the treatment of Pulmonary Arterial Hypertension (PAH). These tablets serve as oral pharmaceutical formulations designed to address the unique medical condition of PAH. In May 2022, Zydus, an India-based pharmaceutical company, achieved approval from the US Food and Drug Administration (FDA) for Selexipag tablets. Selexipag is indicated for use in adults to manage Pulmonary Arterial Hypertension, with the goal of delaying disease progression and reducing the likelihood of hospitalization associated with PAH. As a prostacyclin receptor agonist, this medication contributes to the comprehensive management of PAH.

In September 2021, Azurity Pharmaceuticals Inc., a US-based specialty pharmaceutical company, executed the acquisition of Arbor Pharmaceuticals LLC in. The acquisition, undertaken for an undisclosed amount, has positioned Azurity Pharmaceuticals Inc. to establish a prominent business that delivers cutting-edge, high-value pharmaceutical products. Arbor Pharmaceuticals LLC, the acquired company, specializes in providing calcium channel blocking agents, aligning with the broader goals of Azurity Pharmaceuticals Inc. to cater to the specific needs of patients with underserved illnesses. This strategic acquisition reinforces Azurity Pharmaceuticals Inc.'s commitment to advancing its product portfolio and addressing critical medical conditions within the calcium channel blocker market.

Major companies operating in the calcium channel blocker market report are Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bausch Health Companies Inc., Lupin Pharmaceuticals Inc., Cadila Healthcare Limited, Covis Pharma BV, Mylan N.V., Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Sofgen Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Knoll Healthcare Private Limited, Sanofi S.A., Clearsynth Labs Ltd., Searle LLC, Bayer AG, AstraZeneca plc, Wyeth-Ayerst Lederle Inc., GlaxoSmithKline Plc., AbbVie Inc., Silvergate Pharmaceuticals Inc., Exela Pharma Sciences LLC, Arbor Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Drägerwerk AG & Co. KGaA, Fresenius Kabi AG, General Electric Company, Koninklijke Philips N.V., MAQUET Holding B.V. & Co. KG, Medtronic plc, AKAS Medical, Smiths Medical International Limited.

North America was the largest region in the calcium channel blocker market in 2023. The regions covered in the calcium channel blocker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the calcium channel blocker market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

These drugs belong to different classes including dihydropyridine, benzothiazepine, phenylalkylamine, and others. Dihydropyridines specifically function by blocking calcium channels present in the muscle cells of the heart and arterial blood vessels, thereby reducing the influx of calcium ions into these cells. These medications are indicated for conditions such as hypertension (high blood pressure), chest pain, and certain types of arrhythmias. They are typically administered orally, through parenteral routes, or by other methods, and are utilized by hospitals, homecare settings, specialty clinics, and other end-users for medical purposes.

The calcium channel blocker market research report is one of a series of new reports that provides calcium channel blocker market statistics, including calcium channel blocker industry global market size, regional shares, competitors with calcium channel blocker market share, detailed calcium channel blocker market segments, market trends, and opportunities, and any further data you may need to thrive in the calcium channel blocker industry. This calcium channel blocker market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.